Dr. Kirman answers questions about Age-Related Macular Degeneration for AMD Awareness Month.
"AMD is the leading cause of vision loss for patients 65 and older. There are good treatments available now. To lower your risk of vision loss: quit smoking, maintain healthy blood pressure, blood sugar, cholesterol, UV protection, weight control, and eye vitamin therapy. Kirman Eye is a leader in early AMD detection using the AdaptDx instrument."
-Dr. Gary Kirman
The AdaptDx instrument is used to objectively measure retinal function based on dark adaptation (recovery of visual function when going from light to darkness). Patients with early stages of age related macular degeneration (AMD), retinitis pigmentosa (RP), and other diseases of the retina can have reduced dark adaptation function. This is an "early warning device" in predicting your risk of future AMD. This valuable data will help your doctor assess your risk for AMD, RP, and other retinal diseases. The AdaptDx is helpful in early detection of problems that may not be found with other instruments until later in the disease process when vision has already been affected.
Testing Time Frame: Varies by individual, may take up to an hour
PA State Rep. John Payne at Kirman Eye to discuss breakthroughs in medical technology which detects macular degeneration earlier and ultimately can lead to preventing blindness.
Our office was proud to host this press conference on September 8, 2014 with State Representative John Payne and other special guests. We were one of the first in the country to offer this new technology. The Maculogix AdaptDx is capable of detecting early risk of macular degeneration (central vision loss).
Optical Coherence Tomography
Optical coherence tomography (OCT) is a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina.
With OCT, we can see each of the retina’s distinctive layers. This allows our optometrists to map them and measure their thickness. These measurements help with diagnosis. They also provide treatment guidance for glaucoma and diseases of the retina. These retinal diseases include age-related macular degeneration (AMD) and diabetic eye disease.
Testing Time Frame: Varies by individual, scanning usually takes about 5 – 15 minutes.
The QuantifEye instrument measures Macular Pigment Optical Density (MPOD) in the retina (back of the eye). If you think of the retina as a target, the macular area is the "bullseye." The macula is responsible for our central vision (20/20 vision) and most of our color vision. Normal macular pigment levels effectively block harmful blue light from reaching the visual cells in the macular area, reducing the risk of damage to your central vision. Low macular pigment levels are highly associated with age related macular degeneration (AMD) and poor night vision performance such as glare and haloing while driving at night.
This device determines your MPOD score which helps your doctor to assess your risk of age related macular degeneration as well as your degree of decreased night vision performance. This MPOD measurement also helps to determine whether you are a candidate for dietary supplements for the eye. Specialized eye supplements are prescribed by your doctor to increase your MPOD score to lower your risk of developing AMD. The supplements can also improve night vision performance.
Testing Time Frame: 10-15 minutes
The optomap® retinal image gives the Kirman Eye professionals a much larger view (200 degrees) of the back of the eye – your retina – than conventional eye exam equipment. The images can be taken without dilating your pupils – a very common procedure which is uncomfortable and inconvenient for many people. Each optomap® image is as individual as fingerprints or DNA and can provide eye care professionals with a unique view of your health very quickly and comfortably. The optomap® image is captured in less than one second and is immediately available for you and your doctor to review.
Retinal Health Assessment
The Annidis RHA imaging system uses select wavelength LED scanning to help your doctor see the central retina (located in the back of the eye) like it has never been seen before. RHA technology has been proven to provide information about the deeper layers of the retina that, until now, we have not been able to see. This advanced analysis of your retina and choroid (the vascular layer beneath the retina) allows your doctor to effectively diagnose many potentially sight threatening eye diseases earlier and monitor resulting changes over time. Some conditions that we are able to obtain information for include age related macular degeneration (AMD), glaucoma, diabetes, and cardiovascular disease. Early detection of pathology allows the doctor to prescribe a plan of treatment at the very earliest time to preserve your vision.
Kirman Eye obtained this instrument in 2013 and was the second office in Pennsylvania to utilize the RHA imaging technology to analyze all cell layers of the retina and choroid.
Testing time frame: 10-15 minutes
The Dicon Visual Field Instrument tests your ability to see varied intensities of light throughout your central and peripheral (side) vision in each eye. It measures the integrity of your visual pathway from the retina (back of the eye) through each side of the brain to the visual center in the back of your brain. The equipment uses advanced software to map the area of vision in each eye. The results of the test allow your doctor to determine the sensitivity of your central and side vision. Diseases like glaucoma, age related macular degeneration, multiple sclerosis, stroke, and brain tumors can cause defects in your visual field.Visual field testing is used to monitor the effectiveness of glaucoma treatment, the progression of optic atrophy due to multiple sclerosis, improving or worsening visual effects of a stroke, and other visual pathway disorders over time.
Testing Time Frame: about 30 minutes
Heidelberg Retinal Tomography
The HRT3 instrument is used to detect and monitor diseases of the optic nerve, most commonly glaucoma. Other related diseases that are monitored with the HRT3 include multiple sclerosis, primary optic atrophy, and optic nerve trauma. It is also used to measure edema (swelling) in the macular area (central vision) of the retina. Edema of the macular area may occur in patients with diabetes, hypertension, and age related macular degeneration. This technology uses 65,000 data points to create a topographic analysis of your optic nerve. These precise measurements are accomplished using scanning laser technology. Any minute changes in the optic nerve topography are detected by your doctor. This allows the doctor to begin treatment for conditions like glaucoma. Our doctors' ultimate goal is to preserve your vision.
In 1998, Kirman Eye was the first private practice in Pennsylvania to utilize this advanced testing. Today, the HRT3 continues to be state of the art technology.
Testing time frame: 15-20 minutes